Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.
The present study was designed to examine whether cyclophosphamide augmented induction of antitumor cells and antitumor resistance in C57BL/6 mice pretreated with mitomycin-C-treated EL4 cells (EL4MMC) plus OK-432, a streptococcal preparation. C57BL/6 mice were pretreated with EL4MMC (10(7] plus OK-432 (2.5 KE) i.p. twice at 1-week intervals. When the mice received an i.p. injection of cyclophosphamide at 200 mg/kg 2 days before the last treatment, the antitumor activity of their spleen cells and peritoneal exudate cells (PEC) was effectively augmented 7-8 days after the last treatment. Splenic antitumor activity disappeared 15 days after the last treatment whereas augmented antitumor activity of the PEC was detected even 28 days after the last treatment. This cyclophosphamide effect was dose-dependent and 200 mg/kg was the most effective among the doses tested. If the EL4MMC plus OK-432 treatment was injected at a s.c. site, it was also effective in combination with cyclophosphamide. The antitumor activity of the PEC from s.c.-pretreated mice, however, was lower than that from i.p.-pretreated mice. Despite the fact that cyclophosphamide effectively augmented induction of antitumor cells in C57BL/6 mice pretreated with EL4MMC plus OK-432, it diminished rather than augmented, under all conditions tested, the ability of the mice to resist a challenge of live EL4 cells. Reduction of antitumor resistance by cyclophosphamide was also observed in an experimental system of a semi-syngeneic host (BDF1) tumor (EL4). These results indicate that augmentation of in vivo induction of certain kinds of antitumor cells does not necessarily result in a beneficial augmentation of the host's ability to resist tumor growth.
Ryoyama
K
K
Department of Experimental Therapeutics, Kanazawa University, Japan.
Ryoyama
C
C
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D007111:Immunity, Cellular; D007167:Immunotherapy; D066298:In Vitro Techniques; D051379:Mice; D008810:Mice, Inbred C57BL; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D010844:Picibanil / Q000627:therapeutic use; D013945:Thymoma / Q000276:immunology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000276:immunology / Q000628:therapy*; D014407:Tumor Cells, Cultured / Q000276:immunology
D008937:Mitomycins; D010844:Picibanil; D016685:Mitomycin; D003520:Cyclophosphamide